The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 37 | — | 20.1x | Near average | |
Growth | — | — | 5.6% | No data | |
Quality | 8 | -129.4% | 7.6% | Below average | |
Safety | 53 | 0.2x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Akari Therapeutics, Plc is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Akari Therapeutics, Plc shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Akari Therapeutics stock shows a state of complete stability in analyst targets over the past 30 days, with the target price stabilizing at 1200 dollars based on coverage from only one analyst. This figure reflects a massive gap between the current price (18.27 dollars) and the target, indicating expectations of exceptional growth often linked to clinical results or anticipated mergers, but it lacks confirmation from a broader base of analysts.